Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
-
Narrated by:
-
By:
About this listen
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
- Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet